

Coccidioidomycosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CEDD33A0E041EN.html>

Date: March 2022

Pages: 46

Price: US\$ 2,000.00 (Single User License)

ID: CEDD33A0E041EN

Abstracts

Coccidioidomycosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coccidioidomycosis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Coccidioidomycosis (Infectious Disease) pipeline landscape.

Coccidioidomycosis, also called Valley fever, is an infection caused by the fungus *Coccidioides*. Symptoms include fever, cough, chest pain, chills, headache, fatigue and joint aches. Risk factors include weakened immune system, age, pregnancy, race and environmental exposure. Treatment includes antifungal medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coccidioidomycosis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Coccidioidomycosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coccidioidomycosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coccidioidomycosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Coccidioidomycosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Coccidioidomycosis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Coccidioidomycosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Coccidioidomycosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Coccidioidomycosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Coccidioidomycosis (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Coccidioidomycosis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Coccidioidomycosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Coccidioidomycosis - Overview
- Coccidioidomycosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Coccidioidomycosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Coccidioidomycosis - Companies Involved in Therapeutics Development
- Acea Biotech Inc
- F2G Ltd
- Mayne Pharma Group Ltd
- Mycovia Pharmaceuticals Inc
- Pfizer Inc
- Scynexis Inc
- Valley Fever Solutions Inc
- Coccidioidomycosis - Drug Profiles
- Amphotericin B sodium - Drug Profile
- Product Description
- Mechanism Of Action
- coccidioidomycosis vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- fosmanogepix - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ibrexafungerp citrate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events

itraconazole - Drug Profile

Product Description

Mechanism Of Action

History of Events

nikkomycin Z - Drug Profile

Product Description

Mechanism Of Action

History of Events

olorofim - Drug Profile

Product Description

Mechanism Of Action

History of Events

VT-1598 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Coccidioidomycosis - Dormant Projects

Coccidioidomycosis - Product Development Milestones

Featured News & Press Releases

Oct 22, 2020: F2G receives second US FDA Breakthrough Therapy Designation for Olorofim

Jun 10, 2020: F2G's Olorofim receives both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections

Oct 24, 2019: SCYNEXIS expands FURI protocol to a broader range of refractory serious fungal infections, building on Ibrexafungerp's positive data and favorable toxicology profile observed to date

Sep 09, 2019: FDA grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for seven different indications

Jun 07, 2018: Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host

Jul 13, 2017: FDA Grants Fast Track Designation to VT-1598 for Treatment of Valley Fever

May 17, 2017: Viamet To Present Data on VT-1598 at The American Society for Microbiology's ASM Microbe 2017 Conference

Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

Sep 15, 2016: FDA Grants QIDP Designation to VT-1598 for Treatment of Valley Fever

Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections

May 25, 2016: Viamet Receives Orphan Drug Designation from the FDA for VT-1598 for the Treatment of Coccidioidomycosis

May 20, 2015: Viamet Announces NIH Grant for Compounds Directed at Valley Fever

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Coccidioidomycosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Coccidioidomycosis - Pipeline by Acea Biotech Inc, 2022
Coccidioidomycosis - Pipeline by F2G Ltd, 2022
Coccidioidomycosis - Pipeline by Mayne Pharma Group Ltd, 2022
Coccidioidomycosis - Pipeline by Mycovia Pharmaceuticals Inc, 2022
Coccidioidomycosis - Pipeline by Pfizer Inc, 2022
Coccidioidomycosis - Pipeline by Scynexis Inc, 2022
Coccidioidomycosis - Pipeline by Valley Fever Solutions Inc, 2022
Coccidioidomycosis - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Coccidioidomycosis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Coccidioidomycosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CEDD33A0E041EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CEDD33A0E041EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

